Summary and Conclusion
HF presents with an apparent lung phenotype characterized by thickened walls of small vessels within the lung and an elevation of classically-activated non-alveolar macrophages. Pharmacological CFTR correction with Lum attenuates HF-associated vascular alterations and lowers pro-inflammatory macrophage numbers, while promoting an alternatively-activated phenotype. Collectively, these data suggest pharmacological CFTR correction as promising approach to mitigate HF-induced pulmonary inflammation and associated structural alterations.